BACKGROUND
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by insulin resistance and hyperglycemia due to insufficient ability of pancreatic beta cells to secrete insulin.1According to the latest data released by the International Diabetes Federation (IDF) in 2022, the number of people living with diabetes worldwide has climbed to a staggering 533 million, and is predicted to increase dramatically to 783 million by 2045,2 particularly noteworthy is the fact that over 90% of this large group are diagnosed with type 2 diabetes mellitus (T2DM).3According to authoritative data published by the World Health Organization (WHO), the number of deaths caused by diabetes has almost doubled since 2000, and in particular, the ranking of diabetes as a cause of death in low- and middle-income countries has jumped significantly from 15th to 9th.4Type 2 diabetes mellitus is a chronic disease with complex and variable conditions,5and long-term abnormal fluctuations in blood glucose can cause irreversible damage to target organs, such as cardiovascular, renal, and neurological organs,6and numerous patients suffer from a variety of different types of complications, which poses a serious threat to human health and significantly reduces the quality of life of patients.7-8Moreover, the rising prevalence of type 2 diabetes is exerting enormous pressure on social health systems around the world, and has now risen to the level of a global public health challenge that needs to be urgently addressed.2
OBJECTIVE
To evaluate the digital glucose management model for controlling blood glucose levels in out-of-hospital patients with type 2 diabetes mellitus.
METHODS
A systematic search of PubMed, Embase, Web of Science, CNKI, Wanfang, VIP, CBM, and Cochrane Library for articles published from the establishment of the database to December 25, 2023. Data were extracted independently by two researchers, and the risk of bias in individual trials was rated using the Cochrane risk-of-bias tool . Meta-analysis was conducted by using RevMan 5.3.
RESULTS
Twelve studies were included and 1669 participants were involved. Meta-analysis found that in the digital glucose management group, glycosylated hemoglobin [MD=-0.52, 95%CI=(-0.63 to -0.42), P < 0.00001], Fasting blood sugar [MD=-0.42, 95%CI=(-0.65 to -0.19), P < 0.05], 2h postprandial blood sugar [MD=-0.64, 95%CI=(-0.97 to -0.32), P < 0.0001], body mass index[MD=-1.55, 95%CI=(-2.92 to -0.17), P < 0.05] was better than the control group.
CONCLUSIONS
The digital glucose management model is effective in improving blood glucose levels and body mass index in out-of-hospital patients with type 2 diabetes mellitus.
CLINICALTRIAL
registration:https://www.crd.york.ac.uk/PROSPERO/,CRD42024560431.